TW200722425A - Preparation of (S)-4-fluoromethyl-dihydro-furan-2-one - Google Patents

Preparation of (S)-4-fluoromethyl-dihydro-furan-2-one

Info

Publication number
TW200722425A
TW200722425A TW095118155A TW95118155A TW200722425A TW 200722425 A TW200722425 A TW 200722425A TW 095118155 A TW095118155 A TW 095118155A TW 95118155 A TW95118155 A TW 95118155A TW 200722425 A TW200722425 A TW 200722425A
Authority
TW
Taiwan
Prior art keywords
fluoromethyl
furan
dihydro
preparation
formula
Prior art date
Application number
TW095118155A
Other languages
English (en)
Other versions
TWI310767B (en
Inventor
Stefan Abrecht
Jean-Michel Adam
Alec Fettes
Joseph Foricher
Bruno Lohri
Patrizio Mattei
Gerard Moine
Rudolf Schmid
Ulrich Zutter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200722425A publication Critical patent/TW200722425A/zh
Application granted granted Critical
Publication of TWI310767B publication Critical patent/TWI310767B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095118155A 2005-05-24 2006-05-22 Preparation of (s)-4-fluoromethyl-dihydro-furan-2-one TWI310767B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05104408 2005-05-24

Publications (2)

Publication Number Publication Date
TW200722425A true TW200722425A (en) 2007-06-16
TWI310767B TWI310767B (en) 2009-06-11

Family

ID=36764569

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095118155A TWI310767B (en) 2005-05-24 2006-05-22 Preparation of (s)-4-fluoromethyl-dihydro-furan-2-one

Country Status (15)

Country Link
US (1) US7619101B2 (zh)
EP (1) EP1893595B1 (zh)
JP (1) JP4219975B2 (zh)
KR (1) KR100927910B1 (zh)
CN (1) CN101180282B (zh)
AT (1) ATE407126T1 (zh)
AU (1) AU2006251253B2 (zh)
BR (1) BRPI0611196A2 (zh)
CA (1) CA2607927C (zh)
DE (1) DE602006002612D1 (zh)
ES (1) ES2313672T3 (zh)
IL (1) IL187001A (zh)
MX (1) MX2007014494A (zh)
TW (1) TWI310767B (zh)
WO (1) WO2006125728A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031750A2 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Process for the preparation of pyrido[2,1-a]isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine
US7956201B2 (en) * 2006-11-06 2011-06-07 Hoffman-La Roche Inc. Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
US20090105480A1 (en) * 2007-08-30 2009-04-23 Ulrike Bromberger Process for the preparation of a dpp-iv inhibitor
US20090163718A1 (en) * 2007-12-19 2009-06-25 Stefan Abrecht PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES
CN112898210B (zh) * 2013-11-15 2025-02-21 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
CN108558797B (zh) * 2018-05-28 2020-04-17 华南师范大学 双醚化呋喃酮含氟衍生物及其制备方法与在制备抗肿瘤药物中的应用
CN113620913A (zh) * 2021-07-26 2021-11-09 安徽华业香料股份有限公司 一种γ-壬烯内酯的合成方法
CN117510376A (zh) * 2023-10-17 2024-02-06 四川新迪生物制药有限公司 一种手性联芳基取代的4-氨基-丁酸及其衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016536A1 (de) * 1991-03-15 1992-10-01 F. Hoffmann-La Roche Ag Chirale phosphine
US6545165B1 (en) * 2000-02-04 2003-04-08 Roche Colorado Corporation Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
DE10157533A1 (de) * 2001-11-23 2003-06-05 Bayer Cropscience Ag Verfahren zur Herstellung von chiral, nicht-racemischen 5-substituierten gamma-Butyrolactonen
ITMI20020415A1 (it) * 2002-03-01 2003-09-01 Chemi Spa Catalizzatori metallici per reazione chemo- regio- stereo-selettive erelativi precursori
MXPA05013904A (es) * 2003-06-20 2006-02-24 Hoffmann La Roche Derivados de pirido[2,1-a] isoquinolinas como inhibidores de dipeptidil-peptidasa iv(dpp-iv).

Also Published As

Publication number Publication date
JP4219975B2 (ja) 2009-02-04
CN101180282B (zh) 2011-09-21
KR20080012885A (ko) 2008-02-12
ES2313672T3 (es) 2009-03-01
DE602006002612D1 (de) 2008-10-16
MX2007014494A (es) 2008-02-11
IL187001A0 (en) 2008-02-09
IL187001A (en) 2012-08-30
CN101180282A (zh) 2008-05-14
US7619101B2 (en) 2009-11-17
EP1893595B1 (en) 2008-09-03
AU2006251253A1 (en) 2006-11-30
CA2607927C (en) 2014-12-30
CA2607927A1 (en) 2006-11-30
WO2006125728A1 (en) 2006-11-30
TWI310767B (en) 2009-06-11
JP2008545673A (ja) 2008-12-18
ATE407126T1 (de) 2008-09-15
US20060270853A1 (en) 2006-11-30
AU2006251253B2 (en) 2012-03-15
KR100927910B1 (ko) 2009-11-19
EP1893595A1 (en) 2008-03-05
BRPI0611196A2 (pt) 2010-08-24

Similar Documents

Publication Publication Date Title
TW200734311A (en) New compounds
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2008076046A8 (en) Novel 2-amino-5, 5-diaryl-imidazol-4-ones
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
TW200716596A (en) Substituted amide derivatives and methods of use
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
IL187001A0 (en) Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
TW200606162A (en) Pyrazolopyridine derivatives
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
TW200736213A (en) Dicarboxylic acid derivatives and their use
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
TW200630374A (en) Thiazolyldihydroindazoles
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
WO2009027736A3 (en) 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees